A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353 · clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
110
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie